News

Brain AG raises €60m
Enlarge image

BusinessGermany

Brain AG raises €60m

28.11.2012 - German industrial biotech specialist Brain AG has attracted €60m from its existing investors to beef up for future takeovers.

The capital increase builds one of the cornerstones for the implementation of Brain’s "buy and build“ strategy of industrialisation. A smaller portion of the proceeds will be used to expand the technology platforms of Brain, which are part of projects funded by Germany's federal government.

With its buy and build strategy, Brain tries to cover all steps in the value chain, from research through to product development for market. Brain has already succeeded in building a complete value chain in the field of cosmetics, with the acquisition of Monteil Cosmetics International GmbH. The German biotech company now plans to repeat this success in other areas. It has developed a process that can convert glycerol into 1,2-propanediol. Impure Glycerol is obtained in large quantities in the production of biodiesel and enzymes may convert the alcohol into a de-icing product, which then could be used for de-icing airplane wings. “We have the technology and can organise the production. What we need is someone who has the necessary equipment and has a contract with an airport”, stated Brain’s CEO Holger Zinke.

The money in this financing round comes from existing investors in the company, the family Putsch and the Munich MIG funds. They rely on the current megatrend in the chemical industry: moving away from oil towards biological products and processes. “Recent acquisitions like the purchase of Norwegian Pronova Biopharma by BASF clearly show that the chemical companies with new products move in the direction of the consumer. We want to be part of this movement", says Zinke. On November 21, the world’s largest chemical company announced that it has reached an agreement with Pronova BioPharma ASA’s Board of Directors to make a recommended voluntary public offer, valuing the fish oil producer at NOK4.8bn (€664m).

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2012-04/brain-ag-raises-eur60m.html

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto discussing a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

FinancingBelgium

28.04.2015 After having raised €100m in its stock market debut, MDx company Biocartis has gained 13 percent on its first trading day.

R&DFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.08 CHF14.29%
  • MEDIGENE10.96 EUR4.88%
  • EVOLVA1.58 CHF3.27%

FLOP

  • BIOTEST71.00 EUR-3.92%
  • SYNGENTA314.40 CHF-3.65%
  • 4SC5.03 EUR-3.27%

TOP

  • 4SC5.03 EUR293.0%
  • WILEX4.33 EUR51.4%
  • SARTORIUS151.00 EUR21.2%

FLOP

  • CYTOS1.01 CHF-29.4%
  • BIOTEST71.00 EUR-26.9%
  • BIOFRONTERA2.30 EUR-11.2%

TOP

  • SANTHERA96.45 CHF2329.5%
  • CYTOS1.01 CHF676.9%
  • WILEX4.33 EUR397.7%

FLOP

  • MOLOGEN4.94 EUR-55.4%
  • BIOFRONTERA2.30 EUR-29.2%
  • BIOTEST71.00 EUR-20.0%

No liability assumed, Date: 03.05.2015